Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells $558,129.00 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret Horn sold 3,575 shares of the company’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $156.12, for a total value of $558,129.00. Following the completion of the transaction, the chief operating officer directly owned 154,647 shares in the company, valued at approximately $24,143,489.64. This represents a 2.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Revolution Medicines Price Performance

RVMD stock opened at $162.99 on Friday. Revolution Medicines, Inc. has a fifty-two week low of $34.00 and a fifty-two week high of $166.50. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. The stock has a market capitalization of $34.65 billion, a price-to-earnings ratio of -23.05 and a beta of 1.40. The business’s fifty day moving average price is $147.04 and its two-hundred day moving average price is $113.34.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter last year, the business posted ($1.13) EPS. On average, equities analysts anticipate that Revolution Medicines, Inc. will post -7.94 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RVMD shares. HC Wainwright lifted their price target on shares of Revolution Medicines from $169.00 to $195.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Royal Bank Of Canada raised their price objective on Revolution Medicines from $165.00 to $182.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. Piper Sandler lifted their price objective on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Stifel Nicolaus reiterated a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. Finally, Jefferies Financial Group assumed coverage on Revolution Medicines in a report on Monday, March 16th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Revolution Medicines presently has a consensus rating of “Buy” and an average price target of $123.72.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. General Atlantic L.P. acquired a new stake in shares of Revolution Medicines in the 3rd quarter valued at $115,556,000. Norges Bank acquired a new position in shares of Revolution Medicines during the 4th quarter worth $195,568,000. Avoro Capital Advisors LLC acquired a new position in shares of Revolution Medicines during the 4th quarter worth $172,840,000. UBS Group AG lifted its position in shares of Revolution Medicines by 183.6% during the 4th quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock worth $245,954,000 after buying an additional 1,998,972 shares during the last quarter. Finally, Polar Capital Holdings Plc lifted its position in shares of Revolution Medicines by 321.2% during the 4th quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock worth $160,398,000 after buying an additional 1,535,686 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.